Last reviewed 2026-04-23 · How we verify

Efluelda® Pre-filled syringe

Efluelda is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the natural hormone GLP-1 to regulate blood sugar levels.

Efluelda is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the natural hormone GLP-1 to regulate blood sugar levels. Used for Type 2 diabetes.

At a glance

Mechanism of action

Efluelda works by binding to and activating the GLP-1 receptor, which increases insulin secretion, decreases glucagon secretion, and slows gastric emptying, ultimately lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.

Approved indications

• Type 2 diabetes

Common side effects

• Nausea
• Vomiting
• Diarrhea

Key clinical trials

• Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe
• Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older (PHASE3)
• Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Efluelda® Pre-filled syringe CI brief — competitive landscape report
• Efluelda® Pre-filled syringe updates RSS · CI watch RSS
• Sanofi portfolio CI